[PETDAG] QoQ Quarter Result on 30-Jun-2021 [#2]

Stock
[PETDAG] PETRONAS DAGANGAN BHD
Announcement Date
23-Aug-2021
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2021
Quarter
30-Jun-2021 [#2]
Profit Trend
QoQ- -57.02%
YoY- 2240.2%
Quarter Report
Latest QR
Upcoming QR
PETDAG's Result
PETDAG's Financial Summary
View:
Show?
Quarter Result
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Revenue 7,618,323 7,057,356 5,200,662 5,143,990 5,103,318 4,394,808 4,830,478 35.52%
PBT 178,714 199,807 165,540 89,965 285,456 115,391 288,290 -27.31%
Tax -58,364 -61,722 -45,922 -7,600 -94,292 -27,748 -77,492 -17.23%
NP 120,350 138,085 119,618 82,365 191,164 87,643 210,798 -31.20%
-
NP to SH 118,494 137,191 119,310 82,141 191,113 89,214 212,661 -32.31%
-
Tax Rate 32.66% 30.89% 27.74% 8.45% 33.03% 24.05% 26.88% -
Total Cost 7,497,973 6,919,271 5,081,044 5,061,625 4,912,154 4,307,165 4,619,680 38.14%
-
Net Worth 5,444,127 5,583,211 5,632,884 5,613,015 5,672,622 5,642,818 5,662,687 -2.59%
Dividend
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Div 49,672 258,298 198,690 99,345 139,083 168,887 109,279 -40.91%
Div Payout % 41.92% 188.28% 166.53% 120.94% 72.78% 189.31% 51.39% -
Equity
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Net Worth 5,444,127 5,583,211 5,632,884 5,613,015 5,672,622 5,642,818 5,662,687 -2.59%
NOSH 993,454 993,454 993,454 993,454 993,454 993,454 993,454 0.00%
Ratio Analysis
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
NP Margin 1.58% 1.96% 2.30% 1.60% 3.75% 1.99% 4.36% -
ROE 2.18% 2.46% 2.12% 1.46% 3.37% 1.58% 3.76% -
Per Share
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
RPS 766.85 710.39 523.49 517.79 513.69 442.38 486.23 35.52%
EPS 11.90 13.80 12.00 8.30 19.20 9.00 21.40 -32.40%
DPS 5.00 26.00 20.00 10.00 14.00 17.00 11.00 -40.91%
NAPS 5.48 5.62 5.67 5.65 5.71 5.68 5.70 -2.59%
Adjusted Per Share Value based on latest NOSH - 993,454
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
RPS 766.85 710.39 523.49 517.79 513.69 442.38 486.23 35.52%
EPS 11.90 13.80 12.00 8.30 19.20 9.00 21.40 -32.40%
DPS 5.00 26.00 20.00 10.00 14.00 17.00 11.00 -40.91%
NAPS 5.48 5.62 5.67 5.65 5.71 5.68 5.70 -2.59%
Price Multiplier on Financial Quarter End Date
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Date 31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 -
Price 20.42 20.60 19.12 18.60 20.04 21.40 19.74 -
P/RPS 2.66 2.90 3.65 3.59 3.90 4.84 4.06 -24.58%
P/EPS 171.20 149.17 159.21 224.96 104.17 238.30 92.22 51.10%
EY 0.58 0.67 0.63 0.44 0.96 0.42 1.08 -33.95%
DY 0.24 1.26 1.05 0.54 0.70 0.79 0.56 -43.18%
P/NAPS 3.73 3.67 3.37 3.29 3.51 3.77 3.46 5.14%
Price Multiplier on Announcement Date
31/03/22 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 CAGR
Date 26/05/22 22/02/22 26/11/21 23/08/21 25/05/21 19/02/21 17/11/20 -
Price 21.12 19.98 19.90 18.80 18.82 19.20 19.50 -
P/RPS 2.75 2.81 3.80 3.63 3.66 4.34 4.01 -22.25%
P/EPS 177.07 144.68 165.70 227.38 97.83 213.80 91.10 55.80%
EY 0.56 0.69 0.60 0.44 1.02 0.47 1.10 -36.26%
DY 0.24 1.30 1.01 0.53 0.74 0.89 0.56 -43.18%
P/NAPS 3.85 3.56 3.51 3.33 3.30 3.38 3.42 8.22%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment